Jounce Therapeutics, Inc. (NASDAQ: JNCE)
Some price data may be temporarily unavailable.
Jounce Therapeutics, Inc. Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Jounce Therapeutics, Inc. Company Info
Jounce Therapeutics, Inc.
News & Analysis
Why Jounce Therapeutics Bounced Higher Today
The company gets a regulatory nod that will put $25 million in its pocket.
2 Biotech Stocks Poised to Soar in 2021
These baby biotechs are itching to come out of their shells.
Why Jounce Therapeutics Stock Is Crashing Today
The company announced disappointing news from a phase 2 study.
3 High-Risk, High-Reward Stocks to Add to Your Watch List
These biotechs have a long road ahead, but they just might deliver massive growth.
Got $1,000? Buy These 4 Cancer Stocks
These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.
Here's Why Jounce Therapeutics Rose 39.3% in March
The biopharma announced full-year 2018 operating results.
Here's Why Jounce Therapeutics Fell Over 38% Today
The early-stage company's lead drug candidate disappointed in a phase 1/2 study.
2018 ASCO Conference Roundup
All your Motley Fool coverage of the 2018 ASCO Conference in one place.
Valuation
Earnings Transcripts
Jounce Therapeutics, inc (JNCE) Q3 2021 Earnings Call Transcript
JNCE earnings call for the period ending September 30, 2021.
Jounce Therapeutics, inc (JNCE) Q2 2021 Earnings Call Transcript
JNCE earnings call for the period ending June 30, 2021.
Jounce Therapeutics, Inc. (JNCE) Q1 2021 Earnings Call Transcript
JNCE earnings call for the period ending March 31, 2021.
Jounce Therapeutics, Inc. (JNCE) Q4 2020 Earnings Call Transcript
JNCE earnings call for the period ending February 25, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.